GeoVax Labs Q3 2024 Earnings Report

GeoVax Labs EPS Results

• Actual EPS: -$0.91
• Consensus EPS: -$1.29
• Beat/Miss: Beat by +$0.38
• One Year Ago EPS: -$4.80

GeoVax Labs Revenue Results

• Actual Revenue: $2.79 million
• Expected Revenue: $1.84 million
• Beat/Miss: Beat by +$950.00 thousand
• YoY Revenue Growth: N/A

GeoVax Labs Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes

GeoVax Labs (NASDAQ:GOVX), a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.